The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback